Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease

Biochimica Et Biophysica Acta
Edward C StackRobert J Ferrante

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is no current therapy preventing cumulative neuronal loss. There is substantial evidence that mitochondrial dysfunction, oxidative stress, and associated caspase activity underlie the neurodegeneration observed. One potential drug therapy is the potent free radical scavenger and antioxidant cystamine, which has demonstrated significant clinical potential in models of neurodegenerative disorders and human neurological disease. This study examined the oral efficacy of cystamine in the MPTP and 6-hydroxydopamine neurotoxin models of PD. The neuroprotective effects of cystamine treatment significantly ameliorated nigral neuronal loss, preserved striatal dopaminergic projections, and improved striatal dopamine and metabolite levels, as compared to MPTP alone. Cystamine normalized striatal 8-hydroxy-2'-deoxyguanosine levels and ATP concentrations, consistent with reduced oxidative stress and improved mitochondrial function. Cystamine also protected against MPTP-induced mitochondrial loss, as identified by mitochondrial heat shock protein 70 and superoxide dismutase 2, with concomitant reductions in cytochrome c and caspase-3 activities. The neuroprot...Continue Reading

References

Jan 1, 1991·Free Radical Biology & Medicine·J D Adams, I N Odunze
Mar 1, 1990·Journal of Neurochemistry·A H SchapiraC D Marsden
Aug 16, 1990·Biochemical and Biophysical Research Communications·S IkebeT Ozawa
Mar 1, 1990·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·W A GahlG F Reed
Sep 29, 1989·Biochemical and Biophysical Research Communications·Y MizunoY Kagawa
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M K ShigenagaB N Ames
Dec 1, 1988·Biochemical Pharmacology·Z L RossettiN H Neff
Feb 1, 1989·Journal of Neurochemistry·D T DexterC D Marsden
Jul 18, 1995·Proceedings of the National Academy of Sciences of the United States of America·E BrouilletM F Beal
Jan 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·D T DexterC D Marsden
Oct 18, 1996·Cell·E S AlnemriJ Yuan
Nov 15, 1996·Science·M H PolymeropoulosR C Duvoisin
Apr 1, 1997·Annals of Neurology·G W MillerA I Levey
May 1, 1999·Experimental Neurology·R T MatthewsM F Beal
Feb 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·A HartmannE C Hirsch
Dec 2, 2000·Nature Neuroscience·R BetarbetJ T Greenamyre
May 2, 2001·Nature Reviews. Neuroscience·M F Beal
Nov 8, 2001·Journal of Neurology·E C Wolters
Jan 10, 2002·Journal of Clinical Epidemiology·Alexis ElbazWalter A Rocca
Jul 12, 2002·The New England Journal of Medicine·William A GahlJerry A Schneider
Nov 30, 2002·The Journal of Biological Chemistry·Mathieu LesortGail V W Johnson
Feb 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Eunsung JunnM Maral Mouradian
Apr 1, 2003·Annals of Neurology·M Flint Beal
Apr 1, 2003·Annals of Neurology·William G TattonNadine Tatton
Apr 4, 2003·The New England Journal of Medicine·Robert M Friedlander

❮ Previous
Next ❯

Citations

Jul 30, 2011·Amino Acids·Claudio TabolacciSimone Beninati
May 13, 2009·Journal of Proteome Research·Ashley D ReynoldsHoward E Gendelman
Jun 21, 2011·Parkinson's Disease·Kyota FujitaMami Noda
Dec 19, 2015·Evidence-based Complementary and Alternative Medicine : ECAM·Jing ZhangJinhao Sun
Jan 23, 2015·Evidence-based Complementary and Alternative Medicine : ECAM·Xiao-Gang GongLing Ma
Jul 15, 2016·Parkinson's Disease·Ruixin YangQian Yang
Jan 1, 2015·Biochimica Et Biophysica Acta·Sung-Yup ChoIn-Gyu Kim
Jan 3, 2014·Biochimica Et Biophysica Acta·Li Gan, Jeffrey A Johnson
Feb 18, 2010·Future Neurology·Thomas M JeitnerArthur Jl Cooper
Feb 10, 2010·Journal of Neuroscience Research·Juan Carlos CoronaJavier Díaz-Nido
Jun 1, 2010·Journal of Cellular Biochemistry·Shao-Hsuan KaoBor-Show Tzang
Jun 24, 2010·Journal of Neurochemistry·Mélanie BousquetFrancesca Cicchetti
Jul 31, 2010·Expert Opinion on Therapeutic Targets·Daniela CaccamoRiccardo Ientile
May 7, 2009·Journal of Neurochemistry·Thomas M JeitnerArthur J L Cooper
Mar 21, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ashley D ReynoldsHoward E Gendelman
Dec 3, 2020·Frontiers in Molecular Biosciences·Frances M Smith, Daniel J Kosman
Dec 18, 2010·Pharmacology, Biochemistry, and Behavior·Alfonso DiazIlhuicamina Daniel Limon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.